Post Genomic Technologies in the personalised treatment of Cancer

Harrison, David (Principal Investigator)

Status	Finished
Effective start/end date	1/04/08 → 31/12/12

Funding

UK central government bodies/local authorities, health and hospital authorities: £714,434.00

6 Article

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells
Khalil, H. S., Langdon, S., Goltsov, A., Soininen, T., Harrison, D., Bown, J. & Deeni, Y., 4 Oct 2016, In: Oncotarget.
Research output: Contribution to journal › Article › peer-review

Open Access
File
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models
Koussounadis, A., Langdon, S., Um, I., Kay, C., Francis, K., Harrison, D. & Smith, V. A., 10 Mar 2016, In: BMC Cancer. 16, 1, p. 205
Research output: Contribution to journal › Article › peer-review

Open Access
File
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer
Huang, R., Langdon, S., Tse, M., Mullen, P., Um, I. H., Faratian, D. & Harrison, D., 14 Dec 2015, In: Oncotarget.
Research output: Contribution to journal › Article › peer-review

Open Access
File